Bharat M Chowrira Net Worth

The estimated Net Worth of Bharat M Chowrira is at least $3.3 Milion dollars as of 1 July 2019. Bharat Chowrira owns over 10,000 units of Karuna Therapeutics Inc stock worth over $3,298,300 and over the last 16 years Bharat sold KRTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Bharat Chowrira KRTX stock SEC Form 4 insiders trading

Bharat has made over 1 trades of the Karuna Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Bharat bought 10,000 units of KRTX stock worth $212,100 on 1 July 2019.

The largest trade Bharat's ever made was buying 10,000 units of Karuna Therapeutics Inc stock on 1 July 2019 worth over $212,100. On average, Bharat trades about 2,000 units every 0 days since 2008. As of 1 July 2019 Bharat still owns at least 10,000 units of Karuna Therapeutics Inc stock.

You can see the complete history of Bharat Chowrira stock trades at the bottom of the page.

What's Bharat Chowrira's mailing address?

Bharat's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON, MA, 02110.

Insiders trading at Karuna Therapeutics Inc

Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy oraz Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.

What does Karuna Therapeutics Inc do?

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip

Complete history of Bharat Chowrira stock trades at Nektar Therapeutics i Karuna Therapeutics Inc

Karuna Therapeutics Inc executives and stock owners

Karuna Therapeutics Inc executives and other stock owners filed with the SEC include:

• Steven Paul,
  Chairman of the Board, President, Chief Executive Officer
• Andrew Miller,
  Chief Operating Officer
• Edmund Harrigan,
  Independent Director
• Troy Ignelzi,
  Chief Financial Officer
• Dr. Steven M. Paul M.D.,
  CEO, Pres & Chairman
• Dr. Andrew Craig Miller,
  Co-Founder & COO
• Dr. Stephen K. Brannan,
  Chief Medical Officer
• Dr. Troy A. Ignelzi,
  CFO & Sec.
• Stephen Brannan,
  Chief Medical Officer
• Atul Pande,
  Independent Director
• James Healy,
  Independent Director
• Jeffrey Jonas,
  Director
• Heather Preston,
  Independent Director
• Robert Nelsen,
  Independent Director
• Christopher Coughlin,
  Independent Director
• Laurie Olson,
  Director
• Giorgio Attardo,
  Vice President, CMC and Preclinical Development
• Dr. Ronald N. Marcus M.D.,
  Sr. VP of Medical
• Charmaine Lykins,
  Chief Commercial Officer
• Dr. James E. Audia Ph.D.,
  Head of Medicinal Chemistry & Sr. Adviser
• Dr. Alan Breier,
  Chair of Scientific Advisory Board & Chief Clinical Advisor
• Stephanie Moore,
  VP of HR
• Sharon Sawchak R.N.,
  VP of Clinical Operations & Compliance
• Mia Kelley J.D.,
  VP of Legal Affairs
• Jason Parker Brown,
  VP of Corp. Fin.
• Venture Partners Ix, Llcarc...,
  
• William Meury,
  President and CEO
• Bharat M Chowrira,
  Director
• Venture Partners Ix, Llcarc...,
  
• Charmaine Lykins,
  Chief Commercial Officer
• Health Llc Pure Tech,
  
• David E. Wheadon,
  
• Denice Torres,
  
• William P Jr Kane,
  Chief Commercial Officer
• Jason Parker Brown,
  Chief Financial Officer